Annexin A5 as independent predictive biomarker for subclinical atherosclerosis and endothelial dysfunction in systemic lupus erythematosus patients

Clinical Laboratory

Volumn 59, Issue 3-4, 2013, Pages 359-367

  Valer, Pompilian ^a   Paul, Balanescu ^a   Eugenia, Balanescu ^a   Camelia, Badea ^a  

^a Carol Davila School of Medicine   (Romania)

Author keywords

Annexin A5; Endothelial dysfunction; Subclinical atherosclerosis; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL MARKER; LIPOCORTIN 5; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANNEXIN A5; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

EID: 84876559552     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120521     Document Type: Article

References (40)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60(2):221-5.
2. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 2001;30(6):436-43.
3. Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol, 2001;87(5):663-6.
4. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford) 2003;42:645-51.
5. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation 1997;96:1432-7.
6. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
7. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004;50(1):151-9.
8. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
9. Blann AD. Endothelial cell activation, injury, damage, and dysfunction: separate entity or mutual terms? Blood Coagul Fibrinolysis 2000;11(2):623-30.
10. Tani C, Mosca M, d'Ascanio A, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006;58(3):212-8.
11. Piper MK, Raza K, Nuttall SL, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007;16(2):84-8.
12. Turner E, Dishy V, Chung CP, et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification. Vasc Health Risk Manag 2005;1(4):357-60.
13. Lima DS, Sato EI, Lima VC, Miranda F Jr, Harta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29(2):292-7.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
15. Hanna EB, Glancy DL. ST-segment depression and T-wave inversion: classification, differential diagnosis, and caveats. Cleve Clin J Med 2011;78(6):404-14.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35(6):630-40.
17. Brey RL, Abbott RD, Curb JD, et al. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001;32(8):1701-6.
18. Ghosh P, Kumar A, Kumar S, Aggarwal A, Sinha N, Misra R. Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009;28(11):1259-65.
19. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med;2003;349:2399-406.
20. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7.
21. Souza AW, Harta FS, Miranda F Jr, Sato EI. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005;123(3):137-42.
22. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004:27;110(4):399-404.
23. Hashimoto M, Eto M, Akishita M, et al. Correlation between flow-mediated vasodilatation of the brachial artery and intimamedia thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 1999;19(11):2795-800.
24. Bhatt SP, Handa R, Gulati GS, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006;35(2):128-32.
25. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104(16):1887-93.
26. Bizzaro N, Tonutti E, Villata D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005;129:61-8.
27. Cederholm A, Frostegard J. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann N Y Acad Sci 2007;1108:96-103.
28. Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin-V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005;25(1):198-203.
29. Hrycek A, Cieślik P. Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2012;32(5):1335-42.
30. Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997;177(4):918-23.
31. Frostegárd AG, Su J, von Landenberg P, Frostegárd J. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease. Scand J Rheumatol 2010;39(1):77-83.
32. Van Heerde WL, Reutelingsperger CPM, Maassen C, Lux P, Derksen RHWM, De Groot PG. The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma. J Thromb Haemost 2003;1:532-6.
33. Ewing MM, de Vries MR, Nordzell M, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011;31(1):95-101.
34. Ewing MM, Karper JC, Sampietro ML, et al. Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Atherosclerosis 2012; 221(2):333-40.
35. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003;23:1444-8.
36. van Tits LJ, van Heerde WL, van der Vleuten GM, et al. Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem Biophys Res Commun 2007;11;356(3):674-80.
37. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med 2005;46:2035-50.
38. Gomez-Zumaquero JM, Tinahones FJ, De RE, Camps M, Garrido L, Soriguer FJ. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford) 2004;43:510-3.
39. Laczik R, Szodoray P, Veres K, et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011;20(7):730-5.
40. Freire de Carvalho J, Sherer Y, Shoenfeld Y. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 2007;98:1157-9.